## K013964 Summary

In accordance with the Food and Drug Administration Rule to implement provisions of the Safe Medical Devices Act of 1990 and in conformance with 21 CFR 807, this is to serve as a Summary of Safety and Effectiveness for the CP Medical absorbable seeding spacer product.

Manufacturer:

CP Medical, Inc.

2414 NE Pacific Avenue Portland, OR 97232 PHONE: (503) 232-1555

FAX:

(503) 230-9993

Contact Person:

Mary Ann Greenawalt, Director

Regulatory and Quality

Device Name:

Trade Name:

Absorbable Seeding Spacers

Common Name:

Accessory to applicator and accessory

to radionuclide brachytherapy Source

Proprietary name:

Accu-Space™ or BioSpacer™

Absorbable Seeding Spacers

Classification:

System, applicator, radionuclide, manual & Source, brachytherapy,

radionuclide (accessory to)

Date Prepared:

December 26, 2001

Predicate Device: The predicate device to the CP Medical BioSpacer or Accu-Space seeding spacer is the Accu-Space absorbable seeding spacers, K010621.

**Device Description**: The CP Medical Accu-Space and BioSpacer consists of absorbable spacer material and is a small cylindrical component device utilized to provide space between the radionuclide seeds as they are implanted into the body.

Indications for Use: The absorbable seeding spacers are intended tob e used to maintain a predetermined space between radionuclide seeds for the introduction of seeds into the body during brachytherapy procedures. Seeding spacers are indicated for use in soft tissue or organ tissue but should not be used during cardiovascular or neurological procedures.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

JAN 2 4 2002

Ms. Mary Ann Greenawalt Director, Regulatory and Quality CP Medical P.O. Box 6724 PORTLAND OR 97208 Re: K013964

Trade/Device Name: Absorbable Seeding Spacers

Regulation Number: 21 CFR 892.5730

Regulation Name: Radionuclide brachytherapy source

Regulatory Class: II Product Code: 90 KXK Dated: December 26, 2001 Received: December 28, 2001

## Dear Ms. Greenawalt:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter:

8xx.1xxx	(301) 594-4591
876.2xxx, 3xxx, 4xxx, 5xxx	(301) 594-4616
884.2xxx, 3xxx, 4xxx, 5xxx, 6xxx	(301) 594-4616
892.2xxx, 3xxx, 4xxx, 5xxx	(301) 594-4654
Other	(301) 594-4692

Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <a href="http://www.fda.gov/cdrh/dsma/dsmamain.html">http://www.fda.gov/cdrh/dsma/dsmamain.html</a>.

Sincerely yours,

Vancy C. Brogdon
Nancy C. Brogdon

Director, Division of Reproductive, Abdominal, and Radiological Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

				Page <u>I</u> of <u>I</u>	
510(k) Number (if k	nown):	013964			
Device Name:	Absorbable	Seeding Spac	ers		
Indications for Use	<b>ə</b> :				
the body during brac	ce between ra chytherapy pi	idionuclide see rocedures. Se	eds for the introduce eding spacers are	ction of the seeds into	
Please do no	t write below	this line – con	tinue on another pa	age if necessary	
Concurrence of CDRH, Office of Device Evaluation (ODE)					
Prescription Use	<u></u>	or	Over the Coun	ter Use	
		(per 21 CFI	R 801.109)		
	ision Sign-Off)	rcyc Grog	lon		
and	ision <b>of Reprodu</b> I Rad <b>iological De</b> (k) Num <b>ber</b>	ictive, Abdomina ivices $+0/3$	964		